Oceana Therapeutics is a global company committed to commercializing best-in-class therapeutics with a focus on colorectal, gastroenterology and urological diseases.  An industry pioneer, Oceana Therapeutics is exceptionally well-positioned to pursue worldwide opportunities to identify, acquire, and maximize the therapeutic value of in-market and late-stage development products addressing the needs of healthcare providers and the patients they serve.


Deflux
Deflux® is approved in the U.S, Europe and elsewhere for the treatment of vesicoureteral reflux (VUR), an anatomical bladder defect afflicting children which can cause severe urinary tract infections and irreversible kidney damage…

Solesta
Solesta® is a biocompatible tissue bulking agent developed as minimally invasive treatment for fecal (bowel) incontinence. It is the only injectable gel to be administered in an outpatient setting without the need for anesthesia…

Latest News:
Oceana Therapeutics Announces Definitive Agreement to be Acquired by Salix...

 

 
-